FushenShaMD

PubMed

• 91 citations
  Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
  Connie Lee Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith
  Blood Cancer Journal. 2020-07-17
• 76 citations
  Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.
  Anita Kumar, Fushen Sha, Ahmed Toure, Ahmet Dogan, Andy Ni
  Blood Cancer Journal. 2019-05-20
• 14 citations
  Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
  Anita Kumar, Zhitao Ying, Anna Alperovich, Ahmet Dogan, Paul A. Hamlin
  Haematologica. 2019-04-01

Journal Articles

• Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse  
  Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD..., Blood Cancer J, 5/20/2019
• Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma  
  Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, Pichardo J, Portlock C, Sha F, Zelenetz AD, Zhang Z, Drill E, Woo K, Younes A, Haematologica, 4/2019
• miR-183 potentially inhibits NF-κB1 expression by directly targeting its 3'-untranslated region  
  Sha F, Wu S, Zhang H, Guo X, Acta Biochim Biophys Sin, 10/1/2014

Books/Book Chapters

• Chinese Guidelines on the Diagnosis and Treatment of Lymphoma 
  Chapter: Diagnosis and Treatment of Hodgkin's Lymphoma 
  Page 110 - 120Ma J, Shuang Y, Wu G, Zhu J, Zhu H, Li Z, Qiu L, Shen L, Su L, Chen J, Zhou J, Yi P, Lin T, Lin S, Jin J, Xu B, Gu K, Gao Z, Huang H, Bao H, Wang Z, Fang X, Sha F*, Re...Editors: In Ye Y, Wang M, Long H.China Medical TribuneEdition 2017,2017

Abstracts/Posters

• Impact of PET Imaging and Histological Transformation on the Prognosis of Early Disease Progression in Follicular Lymphoma
  Batlevi CL, Sha F*, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano J, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz G, Noy A, Palomba M, Portlock C,..., International Conference on Malignant Lymphoma (ICML), Lugano, CHE, 6/2019
• Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II...
  Lin T, Sha F, Huang H, Wang Z, Lin S, Li X, Hong X, Fang X, Li F,Peng C, Ren Q, Zhang L, Liu Q, American Society of Clinical Oncology, Chicago, IL, 6/2018
• Randomized, open-label, phase II trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lym...
  Huang H, Li X, Hong H, Wang Z, Fang X, Li F, Peng C, Ren Q, Sha F*, Zhang L, Lin S, Liu Q, Lin T, American Society of Clinical Oncology, Chicago,IL, 1949